Evidence map›Paper›PMID 40416697›Full record

ArticleFrontiers in public health2025

Prevalence and epidemiology of

Daniel Schröder, Sumire Sorano, Elena Shipitsyna, Enesia Banda Chaponda, Daniel Golparian, Ephraim Chikwanda, Vivian Mwewa, Joyce M Mulenga, Mike Chaponda, Chris Smith and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Prevalence ofInfectious disease reports · 2026
    Article
  2. Article
  3. BMJ open · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daniel Schröder *Department of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden.
Sumire Sorano *Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Elena ShipitsynaDepartment of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden.
Enesia Banda ChapondaDepartment of Biological Sciences, University of Zambia, Lusaka, Zambia.
Daniel GolparianDepartment of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden.
Ephraim ChikwandaTropical Diseases Research Centre, Ndola, Zambia.
Vivian MwewaSt. Paul's Mission Hospital, Nchelenge, Zambia.
Joyce M MulengaTropical Diseases Research Centre, Ndola, Zambia.
Mike ChapondaTropical Diseases Research Centre, Ndola, Zambia.
Chris SmithFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Matsui MitsuakiSchool of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
Massimo MirandolaDepartment of Diagnostics and Public Health, University of Verona, Verona, Italy.
Karel BlondeelFaculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Igor ToskinDepartment of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
R Matthew ChicoFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Magnus UnemoDepartment of Laboratory Medicine, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Örebro, Sweden.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Introduction: Methods: A cross-sectional study was conducted at four antenatal care facilities in Nchelenge, Zambia, among 1,021 pregnant women. Vaginal swabs were collected and tested using the Aptima Results: The prevalence of MG was 12.6% (127 of 1,005 valid samples) among the pregnant women. Only 12 MG-positive women (9.4%) had symptoms of a genitourinary infection, which was similar to the frequency of genitourinary symptoms among MG-negative women (6.1%). The rates of Discussion: This study emphasizes the high prevalence of MG among pregnant women in Zambia, but also lack of MRAMs in MG. These findings suggest that azithromycin remains an efficacious treatment option for MG in this population. Nevertheless, continuous surveillance and judicious macrolide use to maintain treatment efficacy are imperative. Further research and sustained monitoring of MG are essential to inform public health strategies and clinical guidelines in Zambia and similar settings worldwide.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialMacrolidesMycoplasma genitaliumMycoplasma InfectionsPregnancy Complications, InfectiousPrenatal CareAdolescentAdultCross-Sectional StudiesFemaleHumansPregnancyPrevalenceYoung AdultZambiaAnti-Bacterial AgentsMacrolidesantenatal careantimicrobial resistanceazithromycinmacrolide resistanceMycoplasma genitaliumpregnancyprevalenceZambia

Identifiers

PMID40416697
PMCPMC12098091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.